Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Payables (2016 - 2025)

Dare Bioscience's Payables history spans 11 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Payables fell 17.53% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 17.53%, while the annual FY2025 figure was $1.2 million, 17.53% down from the prior year.
  • Payables reached $1.2 million in Q4 2025 per DARE's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.5 million in Q2 2023 to a low of $216043.0 in Q2 2021.
  • Average Payables over 5 years is $2.3 million, with a median of $1.9 million recorded in 2024.
  • Peak YoY movement for Payables: tumbled 89.62% in 2021, then skyrocketed 487.05% in 2023.
  • A 5-year view of Payables shows it stood at $2.1 million in 2021, then fell by 3.57% to $2.0 million in 2022, then soared by 66.94% to $3.4 million in 2023, then crashed by 57.0% to $1.5 million in 2024, then decreased by 17.53% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Payables are $1.2 million (Q4 2025), $1.8 million (Q3 2025), and $1.8 million (Q2 2025).